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AT WHAT COST? A REVIEW OF DRUG 
ACQUISITION COST ISSUES IN MODELLED 
ECONOMIC EVALUATIONS.
Wonder M1, Backhouse M2, Gnanasakthy A2
1Novartis Pharmaceuticals, Sydney, Australia; 2Novartis
Pharmaceuticals, Basel, Switzerland
OBJECTIVE: Payers are increasingly using economic evaluation
methods in their decision-making process for new health tech-
nologies. Payers often only have the results from short-term clin-
ical trials at their decision time point. For new drugs for chronic
diseases/conditions such as hypertension, diabetes mellitus &
multiple sclerosis, they may want to see how these beneﬁts trans-
late into long term outcomes via a model (i.e. a modelled 
economic evaluation). The appropriate time horizon for some
modelled evaluations may be greater than the drug’s remaining
patent life. In a situation where the acquisition cost of a new
drug is the major cost driver, the use of an adjusted acquisition
cost after patent expiry could have a major effect on the mod-
elled cost-effectiveness ratio. We set out to review issues associ-
ated with the acquisition costs of (new) drugs in modelled
economic evaluations. METHODS: We reviewed the latest pub-
lished versions of the guidelines of the major drug reimburse-
ment agencies (PBAC, NICE, DQTC, AMCP) and health
economics reference text books (Gold, Drummond, Bootman) as
well as modelled economic evaluations of drugs published in
ISPOR Value in Health in 2003 & 2004 to see how others have
dealt with this issue. RESULTS: Although we could ﬁnd frequent
citations on the discounting of the acquisition cost of drugs if
the time horizon of an evaluation is greater than 12 months, we
found very little discussion on the merits of the adjustment of
drug acquisition costs post patent expiry. CONCLUSION: The
concept of adjusting the acquisition costs of (new) drugs after
their patent expiry in modelled economic evaluations is under-
developed. The merits & demerits of the concept will be dis-
cussed in more detail in the poster.
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USING MARKOV MATRICES TO INTEGRATE RISK/BENEFIT
CONSIDERATIONS OF HEALTH CARE INTERVENTIONS
EVALUATED USING HEALTH-RELATED QUALITY OF 
LIFE INSTRUMENTS
Casado A, Herdman MJ
3D Health Research, Barcelona, Barcelona, Spain
OBJECTIVES: To show how Markov matrices can be used to
quantify and integrate the risks and beneﬁts of health care inter-
ventions when these are measured using health-related quality of
life (HRQOL) instruments. To provide an example of this type
of evaluation for an HRQOL measure which uses Likert scales
for the response options. METHODS: A brief theoretical expla-
nation of the nature and purposes of Markov matrices will be
followed by practical examples of their potential in the ﬁeld of
outcomes research using the COOP-WONCA charts in a hypo-
thetical longitudinal study. RESULTS: Markov matrices deﬁning
between-state transition probabilities (HRQOL dimension score
at each measurement time point) are developed and use of the
matrices will be illustrated by providing quantitative deﬁnitions
and interpretations of the probabilities associated with the prin-
cipal sub-matrices (main diagonal, upper and lower triangles,
upper and lower linear bounds, and simple elements). CON-
CLUSIONS: The use of theoretical deﬁnitions and practical
examples will be useful in introducing and discussing the appli-
cation of Markov matrices as a means of integrating risk and
beneﬁt considerations associated with health care interventions
measured using HRQOL instruments.
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BRIDGING BEYOND REGRESSION–ARTIFICIAL NEURAL
NETWORK IN MAPPING FROM SF-36 TO HEALTH UTILITY
Yu AP1,Yu YF2, Nichol MB3
1University of Southern California, Los Angeles, CA, USA;
2HealthCore, Inc, Wilmington, DE, USA; 3University of Southern
California, School of Pharmacy, Los Angeles, CA, USA
OBJECTIVES: Linear regression was often used to develop
models bridging SF-36 to utility, with assumptions of linearity
and independence among subscales. Artiﬁcial neural networks
(ANN) are capable to detect complex patterns among data, thus
may provide as a promising alternative algorithm to bridge 
from SF-36 subscales to utility. This study is to investigate the
predictive power of an ANN algorithm, in contrast to that of
linear regression. METHODS: Data included a cohort of 6923
Southern California Kaiser Permanente members who ﬁlled both
SF-36 and HUI2 during 1994–1995. A random sample contain-
ing half of total members was used as a training sample to gen-
erate mapping algorithms based on linear models and ANN
respectively, and the other half was used as testing sample to
compare accuracy of prediction between the two methods. Both
models used 8 domain scores plus age and gender as predictors.
Model prediction accuracy was evaluated based on mean
squared error, mean absolute error, percentage of correct pre-
diction within 0.01, 0.03 and 0.1 error range. Observed and 
predicted utility scores by both methods in testing sample were
summarized and compared. This random sample tests were 
conducted multiple times in order to examine the stability of
such cross-validation procedure. RESULTS: The “trained”
neural network model was a 10-3-1 network. After cross-
validation, the mean squared error was 0.128 for linear model
vs. 0.127 for ANN, and absolute error was 0.095 vs. 0.093.
Within 0.01 error range, linear model predicted 8.58% correctly,
and ANN 8.73%. The rates were 23.8% vs. 24.9% with 0.03
error range, and 63.4% vs. 65.4% with 0.10 error range. The
testing process was repeated multiple times and results were
stable. CONCLUSIONS: When testing to an independent
sample, the bridging algorithm based on ANN showed improved
predictive accuracy and can be used as an alternative to linear
prediction algorithm.
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HEALTH CARE AND WORKLOSS COSTS OF OPIOID ABUSE
AMONG AN EMPLOYED POPULATION IN THE US
White AG1, Birnbaum H1, Mareva MN1, Daher M1, Katz N2,
Vallow S3, Schein J3, Doshi D4, Sikirica V3
1Analysis Group, Inc, Boston, MA, USA; 2Inﬂexxion, Inc, Newton, MA,
USA; 3Janssen Medical Affairs, LLC,Titusville, NJ, USA; 4Janssen
Medical Affairs, LLC, San Diego, CA, USA
OBJECTIVES: To describe demographics of opioid abusers, and
compare medical/drug utilization, workloss patterns, and
medical costs of opioid abusers to those of a control group,
1999–2002. METHODS: A claims database of insured patients
was used to identify patients with claims with ICD-9 codes for
opioid abuse (304.0, 304.7, 305.5, and 965.0). In total, 740 such
patients aged 12–64 were identiﬁed. A control group of non-
abusers was selected using a matched sample (by age, gender, and
census region). All costs were calculated from a private payer’s
perspective in 2003 USD. RESULTS: Opioid abusers, compared
to controls, had higher medical and drug utilization. Almost
60% of opioid abusers had claims for opioids, versus 20% for
controls. Prevalence rates for hospital inpatient care for opioid
abusers were 12 times higher than controls (p < 0.01). Opioid
